India · Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 109.69 billion. The enterprise value is 106.07 billion.
| Market Cap | 109.69B |
| Enterprise Value | 106.07B |
Important Dates
The next estimated earnings date is Monday, August 11, 2025.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | Aug 1, 2025 |
Share Statistics
Marksans Pharma has 453.16 million shares outstanding.
| Current Share Class | 453.16M |
| Shares Outstanding | 453.16M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 43.87% |
| Owned by Institutions (%) | 13.19% |
| Float | 214.46M |
Valuation Ratios
The trailing PE ratio is 28.82 and the forward PE ratio is 22.52.
| PE Ratio | 28.82 |
| Forward PE | 22.52 |
| PS Ratio | 4.18 |
| PB Ratio | 4.41 |
| P/TBV Ratio | 4.66 |
| P/FCF Ratio | 325.05 |
| P/OCF Ratio | 53.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.08, with an EV/FCF ratio of 314.33.
| EV / Earnings | 27.87 |
| EV / Sales | 4.04 |
| EV / EBITDA | 20.08 |
| EV / EBIT | 23.82 |
| EV / FCF | 314.33 |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.62 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.61 |
| Debt / FCF | 9.54 |
| Interest Coverage | 38.18 |
Financial Efficiency
Return on equity (ROE) is 16.73% and return on invested capital (ROIC) is 10.82%.
| Return on Equity (ROE) | 16.73% |
| Return on Assets (ROA) | 9.40% |
| Return on Invested Capital (ROIC) | 10.82% |
| Return on Capital Employed (ROCE) | 16.12% |
| Revenue Per Employee | 14.25M |
| Profits Per Employee | 2.07M |
| Employee Count | 1,840 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 1.64 |
Taxes
In the past 12 months, Marksans Pharma has paid 1.21 billion in taxes.
| Income Tax | 1.21B |
| Effective Tax Rate | 24.08% |
Stock Price Statistics
The stock price has increased by +26.90% in the last 52 weeks. The beta is 1.34, so Marksans Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | +26.90% |
| 50-Day Moving Average | 252.83 |
| 200-Day Moving Average | 258.89 |
| Relative Strength Index (RSI) | 35.80 |
| Average Volume (20 Days) | 899,741 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 26.23 billion and earned 3.81 billion in profits. Earnings per share was 8.40.
| Revenue | 26.23B |
| Gross Profit | 14.25B |
| Operating Income | 4.45B |
| Pretax Income | 5.04B |
| Net Income | 3.81B |
| EBITDA | 5.01B |
| EBIT | 4.45B |
| Earnings Per Share (EPS) | 8.40 |
Balance Sheet
The company has 7.06 billion in cash and 3.22 billion in debt, giving a net cash position of 3.84 billion or 8.48 per share.
| Cash & Cash Equivalents | 7.06B |
| Total Debt | 3.22B |
| Net Cash | 3.84B |
| Net Cash Per Share | 8.48 |
| Equity (Book Value) | 24.89B |
| Book Value Per Share | 54.44 |
| Working Capital | 17.27B |
Cash Flow
In the last 12 months, operating cash flow was 2.07 billion and capital expenditures -1.73 billion, giving a free cash flow of 337.45 million.
| Operating Cash Flow | 2.07B |
| Capital Expenditures | -1.73B |
| Free Cash Flow | 337.45M |
| FCF Per Share | 0.74 |
Margins
Gross margin is 54.32%, with operating and profit margins of 16.97% and 14.51%.
| Gross Margin | 54.32% |
| Operating Margin | 16.97% |
| Pretax Margin | 19.21% |
| Profit Margin | 14.51% |
| EBITDA Margin | 19.11% |
| EBIT Margin | 16.97% |
| FCF Margin | 1.29% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.33%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 0.33% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 7.14% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.32% |
| Earnings Yield | 3.47% |
| FCF Yield | 0.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.
| Last Split Date | Mar 11, 2008 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
Marksans Pharma has an Altman Z-Score of 11.1 and a Piotroski F-Score of 4.
| Altman Z-Score | 11.1 |
| Piotroski F-Score | 4 |